Home » FDA Approves Titan’s Opioid Dependency Combination Therapy
FDA Approves Titan’s Opioid Dependency Combination Therapy
June 2, 2016
The FDA has approved Titan Pharmaceuticals’ combination therapy Probuphine for the treatment of opioid dependence.
A buprenorphine implant, Probuphine is designed to provide a constant, low dose of the drug for six months in patients who already take low-to-moderate doses of buprenorphine.
In a clinical study, 63 percent of patients treated with Probuphine had no evidence of illicit opioid use throughout the six months of treatment. Buprenorphine was previously approved only as a pill or a film placed under the tongue or inside of the cheek.
Upcoming Events
-
21Oct